BTMD Quote, Financials, Valuation and Earnings

Astrana Health, Inc. has a net margin of 19.22% compared to biote Corp.'s net margin of 0.11%. biote Corp.'s return on equity of -- beat Astrana Health, Inc.'s return on equity of 1.85%.

biote Corp. has a consensus price target of $4.21, signalling upside risk potential of 90.59%. On the other hand Astrana Health, Inc. has an analysts' consensus of $36.8889 which suggests that it could grow by 35.82%. Given that biote Corp. has higher upside potential than Astrana Health, Inc., analysts believe biote Corp. is more attractive than Astrana Health, Inc..

biote Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.424%.

biote Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. biote Corp. pays -- of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.

biote Corp. quarterly revenues are $48M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. biote Corp.'s net income of $9.2M is higher than Astrana Health, Inc.'s net income of $1.1M. Notably, biote Corp.'s price-to-earnings ratio is 2.78x while Astrana Health, Inc.'s PE ratio is 142.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for biote Corp. is 0.40x versus 0.46x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International, Inc. has a net margin of 19.22% compared to biote Corp.'s net margin of 9.58%. biote Corp.'s return on equity of -- beat Cryo-Cell International, Inc.'s return on equity of --.

biote Corp. has a consensus price target of $4.21, signalling upside risk potential of 90.59%. On the other hand Cryo-Cell International, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 149.27%. Given that Cryo-Cell International, Inc. has higher upside potential than biote Corp., analysts believe Cryo-Cell International, Inc. is more attractive than biote Corp..

biote Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cryo-Cell International, Inc. has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.12%.

biote Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International, Inc. offers a yield of 19.06% to investors and pays a quarterly dividend of $0.15 per share. biote Corp. pays -- of its earnings as a dividend. Cryo-Cell International, Inc. pays out 510.2% of its earnings as a dividend.

biote Corp. quarterly revenues are $48M, which are larger than Cryo-Cell International, Inc. quarterly revenues of $7.8M. biote Corp.'s net income of $9.2M is higher than Cryo-Cell International, Inc.'s net income of $749.4K. Notably, biote Corp.'s price-to-earnings ratio is 2.78x while Cryo-Cell International, Inc.'s PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for biote Corp. is 0.40x versus 0.87x for Cryo-Cell International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners, Inc. has a net margin of 19.22% compared to biote Corp.'s net margin of -20.12%. biote Corp.'s return on equity of -- beat P3 Health Partners, Inc.'s return on equity of -223.63%.

biote Corp. has a consensus price target of $4.21, signalling upside risk potential of 90.59%. On the other hand P3 Health Partners, Inc. has an analysts' consensus of $10.25 which suggests that it could grow by 303.54%. Given that P3 Health Partners, Inc. has higher upside potential than biote Corp., analysts believe P3 Health Partners, Inc. is more attractive than biote Corp..

biote Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison P3 Health Partners, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

biote Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. biote Corp. pays -- of its earnings as a dividend. P3 Health Partners, Inc. pays out -- of its earnings as a dividend.

biote Corp. quarterly revenues are $48M, which are smaller than P3 Health Partners, Inc. quarterly revenues of $345.3M. biote Corp.'s net income of $9.2M is higher than P3 Health Partners, Inc.'s net income of -$69.5M. Notably, biote Corp.'s price-to-earnings ratio is 2.78x while P3 Health Partners, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for biote Corp. is 0.40x versus 0.01x for P3 Health Partners, Inc.. Usually stocks with elevated PS ratios are considered overvalued.